There is very limited knowledge of CSA pharmacokinetics in patients with autoimmune diseases. In this study we provided routine monitoring of whole blood CSA concentrations as a measure of CSA efficacy and toxicity. Whole blood samples were split for comparative analysis by HPLC and RIA respectively. We were able to discern the relationship between whole blood CSA concentrations as measured by the two methods of assay. Furthermore, we studied the steady state pharmacokinetics of oral CSA in 20 patients in order to determine the absorption and disposition characteristics of CSA in the patient population.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL005064-03
Application #
3939453
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code